Dr. John Spinosa Joins Luventix Advisory Board
Luventix, a leading innovator in Intelligent Disease Diagnostics, is delighted to announce that Dr. John Spinosa has joined its Advisory Board.
Dr. Spinosa is a distinguished medical professional with extensive expertise in clinical pathology, diagnostics, and healthcare innovation. With a proven history of advancing medical technologies and guiding strategic initiatives, Dr. Spinosa’s contributions have significantly impacted the fields of healthcare and biotechnology. His insights will play a critical role in steering Luventix’s innovative solutions and strategic growth initiatives.
"We are honored to welcome Dr. John Spinosa to our Advisory Board," said George Holmes, CEO of Luventix. "His deep expertise in clinical and diagnostic sciences will provide invaluable guidance as we continue to develop transformative solutions in our field."
About Luventix
Luventix is a medical diagnostics company utilizing a simple, non-invasive urine test to detect and diagnose diseases through metabolomics modeling. By leveraging proprietary advanced machine learning (ML) modeling techniques, Luventix has the unique ability to analyze data and pinpoint disease-specific signatures within a Digital Twin, bridging the gap between diagnostics and therapeutics, revolutionizing clinical trial recruitment and enabling companion diagnostics as an integral endpoint.
With a commitment to innovation, collaboration, and excellence, Luventix is redefining industry standards and making a meaningful impact on healthcare outcomes. By combining cutting-edge technology with strategic partnerships, Luventix aims to transform the landscape of personalized medicine and accelerate the delivery of life-changing solutions. For more information, please visit www.luventix.com
Media Contact:
